Skip to main content
Midas Edge

Avalo Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 23, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 23, 2026

AVTX$7.70-9.5%Stored close · as of Nov 12, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

Checking your notes…

Page
PART Iii
Item 1. Business1
Item 1A. Risk Factors16
Item 1B. Unresolved Staff Comments58
Item 1C. Cybersecurity58
Item 2. Properties59
Item 3. Legal Proceedings59
Item 4. Mine Safety Disclosures59
PART II60
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities60
Item 6. Reserved61
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations62
Item 7A. Quantitative and Qualitative Disclosures About Market Risk70
Item 8. Financial Statements and Supplementary Data70
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure70
Item 9A. Controls and Procedures70
Item 9B. Other Information71
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection72
PART III73
Item 10. Directors, Executive Officers and Corporate Governance73
Item 11. Executive Compensation79
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters88
Item 13. Certain Relationships and Related Transactions, and Director Independence92
Item 14. Principal Accountant Fees and Services93
PART IV95
Item 15. Exhibits; Financial Statement Schedules95

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.